Q1 Earnings Estimate for Medtronic Issued By Leerink Partnrs

Medtronic plc (NYSE:MDT - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2026 EPS estimates for shares of Medtronic in a research note issued to investors on Monday, June 16th. Leerink Partnrs analyst M. Kratky forecasts that the medical technology company will earn $1.23 per share for the quarter. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. Leerink Partnrs also issued estimates for Medtronic's Q2 2026 earnings at $1.32 EPS, Q3 2026 earnings at $1.38 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $5.55 EPS, Q1 2027 earnings at $1.34 EPS, Q2 2027 earnings at $1.45 EPS, Q3 2027 earnings at $1.53 EPS, Q4 2027 earnings at $1.77 EPS, FY2027 earnings at $6.08 EPS, FY2028 earnings at $6.54 EPS, FY2029 earnings at $6.99 EPS and FY2030 earnings at $7.46 EPS.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 21st. The medical technology company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.04. The business had revenue of $8.93 billion for the quarter, compared to the consensus estimate of $8.81 billion. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. The company's revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.46 earnings per share.

A number of other brokerages have also issued reports on MDT. Mizuho lowered their target price on shares of Medtronic from $100.00 to $98.00 and set an "outperform" rating for the company in a research note on Thursday, May 22nd. Truist Financial lowered their target price on shares of Medtronic from $93.00 to $90.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Royal Bank of Canada lowered their target price on shares of Medtronic from $105.00 to $101.00 and set an "outperform" rating for the company in a research note on Thursday, May 22nd. Robert W. Baird lowered their target price on shares of Medtronic from $94.00 to $92.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Medtronic in a research note on Friday, June 6th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Medtronic currently has a consensus rating of "Moderate Buy" and an average target price of $97.87.

Medtronic Stock Up 0.7%

NYSE MDT opened at $87.92 on Tuesday. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.48. The company has a fifty day moving average of $84.33 and a two-hundred day moving average of $86.27. The firm has a market capitalization of $112.76 billion, a price-to-earnings ratio of 26.72, a PEG ratio of 2.22 and a beta of 0.79. Medtronic has a 52 week low of $75.96 and a 52 week high of $96.25.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be given a $0.71 dividend. This is an increase from Medtronic's previous quarterly dividend of $0.70. This represents a $2.84 annualized dividend and a dividend yield of 3.23%. The ex-dividend date is Friday, June 27th. Medtronic's dividend payout ratio is currently 78.45%.

Institutional Trading of Medtronic

Several institutional investors and hedge funds have recently made changes to their positions in MDT. 1248 Management LLC purchased a new position in Medtronic during the first quarter worth about $26,000. Burkett Financial Services LLC raised its holdings in shares of Medtronic by 185.0% in the 1st quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company's stock worth $26,000 after purchasing an additional 185 shares during the period. Columbia River Financial Group LLC purchased a new position in shares of Medtronic in the 1st quarter worth about $28,000. Twin Tree Management LP purchased a new position in shares of Medtronic in the 1st quarter worth about $29,000. Finally, Mainstream Capital Management LLC purchased a new position in shares of Medtronic in the 4th quarter worth about $26,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.